The RAC 3-Pillar Trifecta, page-413

I think there are two aspects:

1. The performance of the drug for inhibiting FTO and hence killing or slowing the growth of cancer cells. This means testing Bisantrene in-vitro both individually and in combination with other cancer drugs ( e.g. Keytruda or Opdivo ).
   
   
   
   
2. Determining the biomarkers / tests required for each targeted cancer type to aid in diagnosis of individuals with the genetic traits where inhibiting FTO will help with treatment of their cancer.
   
   
   
   There are likely other biomarkers relevant to each cancer. For example biomarkers related to the VHL gene for ccrCC.
   
   

We know from the November AGM they are looking at Melanoma and ccRCC, but we also know from the November 2020 preclinical Breast Cancer announcement that they have been doing further studies looking at FTO and Breast Cancer (3 months is probably enough time to get some results in-vitro).




I think there could be up to six areas where we could get preclinical results:

1. Significance of FTO for Breast Cancer and testing of drug combinations
2. Relevant biomarkers for FTO and Breast Cancer
3. Testing of Bisantrene as a single agent and in drug combinations for Melanoma
4. Relevant biomarkers for FTO and Melanoma
5. Testing of Bisantrene as a single agent and in drug combinations for ccRCC
6. Relevant biomarkers for FTO and ccRCC

I'm leaning towards an announcement focused on FTO and Breast Cancer ( #1, #2 ) since it's confirmed from the November 2020 announcement they were doing further preclinical study on FTO and Breast Cancer. It's also logically a priority given they priority they have on a Breast Cancer trial ( there may be data they want to capture or it may inform their trial plans ).

I think there will be newsflow on #3 to #6 later in the year.